Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Vigil, Atezolizumab; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: CPX-351; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Nemtabrutinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Head and Neck Cancer
Interventions: Fenretinide (4-HPR), SCH66336; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Sofosbuvir, Ribavirin, and Stribild; Drug
Lead sponsor: Saint Michael's Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Selinexor; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 27
States / cities: Irvine, California • Laguna Hills, California • Orange, California + 22 more

Conditions: Multiple Myeloma
Interventions: CX-4945; Drug
Lead sponsor: Cylene Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Kettering, Ohio • Portland, Oregon • Springfield, Oregon + 3 more

Conditions: Healthy
Interventions: CORT125134 150 mg, CORT125134 250 mg, CORT125134 dose to be determined; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 10
States / cities: Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more

Conditions: Plaque Psoriasis
Interventions: PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Subjects
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type 2 Diabetes Mellitus
Interventions: MEDI0382 Formulation 2, MEDI0382 Formulation 3; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Critical Limb Ischemia
Interventions: RJX, Placebo; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Respiratory Syncytial Virus Immunization
Interventions: RSV vaccine candidate, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 865 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 25
States / cities: Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more

Conditions: Healthy
Interventions: ABT-874; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Volunteers
Interventions: Teprotumumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions: Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 60 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: doxorubicin hydrochloride, cyclophosphamide, filgrastim, paclitaxel albumin-stabilized nanoparticle formulation, trastuzumab, laboratory biomarker analysis, quality-of-life assessment; Drug · Biological · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Letrozole, Placebo, Taselisib; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more

Conditions: Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
Interventions: iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab; Genetic · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Healthy
Interventions: Nalmefene; Drug
Lead sponsor: Tharimmune Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetic Macular Edema
Interventions: triamcinolone acetonide; Drug
Lead sponsor: SurModics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 4
States / cities: Phoenix, Arizona • Santa Barbara, California • Detroit, Michigan + 1 more

Conditions: Healthy Volunteer
Interventions: GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Influenza, Human
Interventions: FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more

Search by objective public record fields.

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Bioavailability and Food Effect Study of 3 Types of Carisbamate

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Phase 1 BA Study, Single Center With Healthy Volunteers

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

An Evaluation of The Absolute Bioavailability of TH104

Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older